Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [11C]ABP688

C DeLorenzo1, 2, J Sovago3, J Gardus2, J Xu4, J Yang5, R Behrje6, JSD Kumar1, DP Devanand1, GH Pelton1, CA Mathis7, NS Mason7, B Gomez-Mancilla3, H Aizenstein7, JJ Mann1 and RV Parsey2

INTRODUCTION

As the population ages, focus is increasing on management of late-life depression.1 Major depressive disorder (MDD) is common in older populations worldwide and can decrease the quality of life, as well as worsen medical outcomes, decrease physical, cognitive and social functioning, and increase risk of suicide.1–3 Although estimates of prevalence vary based on diagnostic criteria used and characteristics of the population under study, MDD rates as high as 42% have been reported in older adults.2, 3

Multiple studies have explored differences in MDD symptoms between adult and elderly populations, as well as the variable behavioral characteristics associated with early- and late-onset depression in the elderly.4, 5 A recent study has also evaluated structural brain changes associated with depression and Alzheimer’s disease in the elderly.6 Yet, little is known about neurochemical differences that may exist in elderly depression. Therefore, to aid in treatment and potentially prevention, it is necessary to explore depression pathophysiology in elderly individuals.

Metabotropic glutamate receptors (mGluRs) have been implicated in the underlying pathology of a number of neurological and psychiatric disorders, including MDD.7 In particular, animal data suggest that one such receptor, the mGluR subtype 5 (mGluR5), may be a potential target for the treatment of anxiety-related and affective disorders.7 Preclinical studies showed that mGluR5 antagonists can promote an antidepressant response in rodents8–12 and that mGluR5 knockout mice exhibit antidepressant-like behavior.12 Lower mGluR5 density has also recently been reported in the brain of individuals with MDD (average age: 40.8 years) compared with healthy volunteers.13 Further, using positron emission tomography (PET), two rapid antidepressant strategies, sleep deprivation (wake therapy) and infusion of ketamine, have been shown to induce changes in binding at mGluR5, implicating this receptor in their mechanism of action.14, 15

Despite diverse evidence linking mGluR5 to MDD and antidepressant action, only a handful of studies have evaluated this receptor in aging/the elderly. A cognitive aging study in rats assessed spatial-memory faculties. Using quantitative immunofluorescence imaging of excised hippocampal sections from aged and young control rats, the study found comparable hippocampal mGluR5 levels in unimpaired aged and young rats, whereas impaired aged rats had only 56% of the level of young rats.16 Another study probed striatal mGluR5 densities in 3- and 24-month-old rats. Using western blotting and chemiluminescence, a 28.8% lower striatal mGluR5 was found in the elder rodents.17 In humans, a post-mortem study evaluated mGluR5 in elderly participants without disease by quantifying the percentage of mGluR5-expressing neurons in the caudate nucleus. In young subjects (n = 3, average age = 30.3), 40% of caudate nucleus neurons expressed mGluR5 receptors, compared with 80% in elderly subjects (n = 6, average age = 78.2).18 However, a recent in vivo PET study reported no statistically significant association.
between age and [11C]ABP688 binding. To our knowledge, no study has examined mGluR5 in elderly depression. In this pilot study, [11C]ABP688 and PET were used to assess regional differences in mGluR5 binding in the brain of elderly patients with MDD compared with elderly healthy volunteers. ABP688 is an mGluR5 antagonist that binds to an allosteric site of the receptor with high affinity and high specificity. Preclinical studies in rats and baboons and results from the recent PET studies in humans demonstrate that [11C]ABP688 is suitable to measure mGluR5 availability in the brain. Differences in [11C]ABP688 binding between patients with early- and late-onset depression were also assessed.

MATERIALS AND METHODS

Study design

This was a pilot study designed to estimate regional distributions of mGluR5 in the brain ([ABP688A2102; ClinicalTrials.gov identifier: NCT01528241]). The study was conducted at the following two centers: Columbia University, New York, NY, USA and the University of Pittsburgh, Pittsburgh, PA, USA.

Participants

Male and female subjects aged 55–80 years with and without MDD were eligible to participate in this study. Twenty elderly (mean age: 63.0 ± 6.3; 11 recruited at the Columbia University) subjects with MDD and 22 elderly (mean age: 66.4 ± 7.3; 12 recruited at the Columbia University) healthy volunteers completed the study. All subjects were required to be non- or light-smokers, consuming six or fewer cups of coffee a day, and in good general health as determined by past medical history and physical examination, vital signs, electrocardiogram and laboratory tests at screening. If the lab values were within 10% of normal range and are not deemed clinically significant by senior clinical staff and the subject was otherwise in healthy condition, the subject was included in the study. Subjects could not have any surgical or medical condition, which might significantly alter the distribution, metabolism or excretion of [11C]ABP688 or which may jeopardize the subject in case of participation in the study. Other general exclusion criteria consisted of the following: use of psychotropic prescription drugs within 2 weeks before the PET scan or use of other prescribed drugs or over-the-counter medication if deemed to affect study results; presence and/or history of a clinically significant major neurological or psychiatric (for controls) disorder; presence and/or history of symptoms consistent with mild cognitive impairment or dementia as evidenced by either a Montreal Cognitive Assessment score of 25 or less or a Mini-Mental State Examination (MMSE) score of 26 or less; or any significant illness within 2 weeks before imaging.

Diagnosis of MDD, either a single episode or recurrent, was based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria and was established by the Structured Clinical Interview for DSM-IV (SCID). Patients were required to score at least 16 on the 17-item Hamilton Depression Rating Scale (HAM-D) and at least 4 (moderately ill) on the Clinical Global Impression Scale (CGI-S).

Exclusion criteria specific to MDD subjects included the following: presence and/or history of clinically significant major psychiatric disorder, other than MDD or generalized anxiety disorder; active suicidal ideation and plan; responding satisfactorily to antidepressant or antianxiety treatment or inability to tolerate medication washout. Subjects receiving benefit from antidepressant medications were not enrolled. If the current medication regimen failed, subjects were washed off of these medications, under the supervision of a clinician.

All participants provided written informed consent before study participation. The study was conducted in compliance with the Good Clinical Practice guidelines and was approved by the Ethics Committee/Institutional Review Board of both participating centers.

PET and MRI examinations

[11C]ABP688 was prepared as previously described. A single bolus injection was administered to each subject, with administered radioactivity between 173 and 630 MBq. The mean (s.d.) administered activity of [11C]ABP688 was 368.81 (84.51) MBq and 387.54 (112.92) MBq for healthy volunteers and patients with MDD (P = 0.54), respectively. The specific radioactivity of [11C]ABP688 was 16–175 GBq μmol⁻¹. The mean (s.d.) specific activity was 53.27 (38.53) GBq μmol⁻¹ and 60.63 (38.93) GBq μmol⁻¹ for healthy volunteers and patients with MDD (P = 0.54), respectively. Each injection was ~10 ml containing between 0.34 and 5.45 μg of ABP688. The range of injected doses and/or specific activities should not affect binding, as there was no observed relationship between average activity and either of these quantities. The mean (s.d.) injected mass was 2.31 (1.20) μg and 2.18 (1.41) μg for healthy volunteers and patients with MDD (P = 0.80), respectively.

PET imaging was performed using an ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN, USA) system at both sites. Following a 10-min transmission scan for attenuation correction, [11C]ABP688 was administered and emission data were collected for 60 min (10×1 min and 10×5 min frames). PET images were reconstructed using filtered back-projection, as previously described.

All subjects received a magnetic resonance imaging (MRI) scan for anatomical reference and to exclude any structural brain abnormalities. MRI images were acquired on a Siemens 3T scanner (University of Pittsburgh, repetition time (TR), 2200 ms; echo time (TE), 3.43 ms; flip angle (FA), 9°; matrix, 256 × 192; voxel size, 1 mm isotropic) and a GE 3T Signa HDx system (Columbia University, TR, 7.344 ms; TE, 2.988 ms; FA, 9°; matrix, 256 × 256; voxel size, 1 mm isotropic). Use of the same PET scanner at each site allowed comparable PET-based measurements. Although the MRI scanner was different, MRIs were solely used for anatomical delineation, and with the same resolution, scanner differences were unlikely to affect outcome.

Blood sampling and metabolite measurements

Before study initiation, both sites standardized methods to ensure that blood acquisition and analysis occurred identically across sites. If possible, a catheter was inserted in the radial artery for blood sampling. Arterial samples were collected automatically within the first 4 min and manually thereafter (Columbia University) or entirely manually (University of Pittsburgh).

Authentic tracer and labeled metabolites in the plasma were separated using Waters Sep-Pak T1 cartridges as described. Unmetabolized parent fraction extraction levels were fit with a Hills function. The input function was calculated as the product of the interpolated parent fraction and the total plasma counts. These combined data were then fit as the combination of a straight line and the sum of three exponentials, describing the function before and after the peak, respectively.

For five subjects with plasma data, metabolite data were not available; therefore, an analytical method was implemented to substitute for the missing data, similar to previous studies. Average arterial metabolite (population) curves were used to fit the standard two-tissue compartment model (2TCM). For comparison purposes, the population curve was also applied to subjects with complete metabolite data, and percentage difference between results obtained with individual and population curves calculated. Comparison of imaging results (binding potential relative to the non-displaceable compartment) with population and individual metabolite curves showed an average absolute percent difference ranging between 3.68 ± 6.04% (dorsal putamen) and 8.76 ± 25.04% (medial prefrontal cortex).

Image analysis

To standardize study results, all images were analyzed by a single center (Columbia University) regardless of location of acquisition by image analysts who were blinded to diagnosis, using MATLAB (The MathWorks, Natick, MA, USA). Motion correction, co-registration to the MRI and automatic, atlas-based regional delineation of the MRI were performed as previously described. All processing steps were visually inspected for accuracy, or manually corrected as needed, before PET-binding analysis. For subjects with arterial blood sampling (and either individual or population-based metabolite values), the standard 2TCM was used to calculate the total volume of distribution (Vt: ratio of the concentration of the ligand in the region of interest to that in the plasma at equilibrium) in each region of interest. S.e. values of the Vt measurement were computed using a bootstrap algorithm that takes into account errors in metabolite, plasma and brain data. To compare Vt to binding estimated in the absence of blood sampling, distribution volume ratio (DVR) was calculated by dividing regional Vt with Vt in the gray matter of the cerebellum. An in vitro receptor-binding study showed that mGluR5s were present in the cerebellum in rat, rhesus monkey and human brain. Further examination using blocking experiments in baboons suggests that ~30%
of cerebellar binding is specific binding, and that binding in the cerebellar gray matter may be lower than that of the full cerebellum.\(^{14}\) Therefore, the gray matter of the cerebellum was chosen as the most suitable reference region in humans. A brain region devoid of specific binding was not identified, and hence an ideal reference region for \(^{11}C\)ABP688 has not been identified. Despite this, DVR was successfully used in previous clinical PET studies to quantify mGluR5 availability in the brain.\(^ {13,33}\)

The reference region-based Logan method\(^ {34}\) was used to calculate DVR (henceforth DVR’ to distinguish from 2TCM results) in subjects without arterial sampling. The results of the Logan analysis were compared against the 2TCM results and were subsequently used to quantify \(^{11}C\)ABP688 binding for all subjects.

DVR and DVR’ were calculated for pre-defined brain regions including the following: dorsal caudate nucleus, dorsal putamen, ventral striatum, cingulate gyrus, hippocampus, amygdala, dorsolateral prefrontal cortex, orbital prefrontal cortex, medial prefrontal cortex temporal lobe, and parietal lobe.

SPM analysis

A voxel-wise comparison of mGluR5 availability between the two cohorts was also performed using Statistical Parametric Mapping (SPMS).\(^ {35}\)

Parametric images of DVR’ were generated for all subjects using the Logan method with the gray matter of the cerebellum as reference region. The voxel maps were co-registered to the corresponding MRI images as described above. Each MRI was transformed into a high-resolution template space Montreal Neurological Institute space using the Advanced Normalization Tools package.\(^ {36}\) Using the PET-to-MRI co-registration transformation and nonrigid MRI transformation, all voxel maps were brought into the high-resolution template space. Voxel maps were smoothed using an 8-mm Gaussian kernel. A two-sample t-test was used to assess differences between MDD patients and healthy volunteers. No global normalization or grand mean scaling was used. Significant differences between the groups were accepted at \(\alpha = 0.05\) after Gaussian random field correction.

Symptomatology assessments

The following psychiatric scales were administered at the time of screening (within 3 weeks of the PET scan) to confirm eligibility for the study: CGI-S, Hamilton Depression Scale (HAM-D), Montreal Cognitive Assessment (MoCA) and the MMSE. In addition to the above scales, within 1 day of the PET scan, the following scales were assessed in the depressed cohort only to evaluate correlations between psychiatric symptoms and regional variations in mGluR5 density: Geriatric Depression Scale (GDS), Beck Suicidal Ideation Scale (BSIS), Generalized Anxiety Disorder Severity Scale (GADSS), Hamilton Anxiety Scale (HAM-A), Penn State Worry Questionnaire (PSWQ), State Trait Anxiety Scale (STAS) and Symptom Checklist-90-Revised (SCL-90).

Statistical analysis

Assuming normal data distribution and an \(\alpha = 0.1\) (two-sided) for this pilot study, a sample of 22 healthy volunteers and 22 patients with MDD would provide 80% power to show a statistically significant difference if the true differences in the means between the patient groups and the healthy volunteers is 6.6–10.1%. A difference of 10% between groups was considered to be of clinical interest.

The agreement between results of the 2TCM, using the population average metabolite values (or individual’s values when available), and those of the Logan analysis was tested graphically by scatter plot between the two parameters, and quantitatively by Pearson product–moment correlation.

For the primary end point, a linear mixed model, taking into account center, brain region, sex, age, and center-by-se outcome, was used to test the primary hypothesis. The random effects were included to account for differences in the between-subject variability.

RESULTS

Healthy volunteers (\(N = 22\)) and patients with MDD (\(N = 20\)) completed the study and were comparable in terms of baseline characteristics and demographics (Table 1).

Analysis of imaging data

A 2TCM was used to calculate regional \(V_T\) values for 16 healthy volunteers (73%) and 14 patients with MDD (70%) for whom arterial blood samples were available. \(V_T\) in the gray matter of the cerebellum did not differ between healthy volunteers and patients with MDD. In general, the correlation coefficients (Table 1) and scatter plots for individual patients (data not shown) showed good agreement between DVR (2TCM) and DVR’ (reference Logan method) with the average correlation between the two measures being 0.79 (0.08) and 0.84 (0.18), for healthy volunteers and MDD subjects, respectively. Therefore, DVR’ values from the reference Logan analysis were used for most statistical analyses as this variable does not require an arterial input function and was available for all subjects (Table 2).

The mean regional DVR’ values varied between 1.56 and 1.79. The lowest average DVR’ values were obtained from the hippocampus and the highest were measured in the striatum (ventral striatum and putamen; Table 2 and Figure 1). Across regions, DVR’ of depressed subjects was between 0.4 and 4.6% larger than the controls. Similarly, \(V_T\) of depressed subjects was between 7.2 and 24.3% greater than the controls. However, the

Table 1. Demographic summary by study group (total population)

|                         | Patients with MDD (\(N = 20\)) | Healthy volunteers (\(N = 22\)) | Total (\(N = 42\)) | P-value |
|-------------------------|---------------------------------|---------------------------------|--------------------|--------|
| **Age (years)**         |                                 |                                 |                    |        |
| Mean (s.d.)             | 63.0 (6.33)                     | 66.4 (7.30)                     | 64.8 (6.98)        | 0.120* |
| Range                   | 55–80                           | 55–78                           | 55–80              |        |
| **Gender, n (%)**       |                                 |                                 |                    | 0.275b |
| Female                  | 15 (75.0)                       | 13 (59.1)                       | 28 (66.7)          |        |
| Male                    | 5 (25.0)                        | 9 (40.9)                        | 14 (33.3)          |        |
| **Race, n (%)**         |                                 |                                 |                    |        |
| Caucasian               | 13 (65.0)                       | 17 (77.3)                       | 30 (71.4)          | —      |
| Black                   | 6 (30.0)                        | 4 (18.2)                        | 10 (23.8)          |        |
| Asian                   | 1 (5.0)                         | 0 (0.0)                         | 1 (2.4)            |        |
| Other                   | 0 (0.0)                         | 1 (4.5)                         | 1 (2.4)            |        |
| **Weight (kg)**         | 81.8 (17.908)                   | 81.02 (14.052)                  | 82.05 (15.841)     |        |
| Range                   | 61.6–122.9                      | 62.5–116.6                      | 61.6–122.9         |        |
| **Height (cm)**         | 166.7 (6.964)                   | 168.6 (8.09)                    | 167.7 (8.81)       |        |
| Range                   | 149–180                         | 156–180                         | 149–180            |        |

Abbreviation: MDD, major depressive disorder. *P-value is from a two-sample t-test. \(^{b}\)P-value is from a \(x^2\)-test.
Table 2. DVR (2TCM method) and DVR’ values (Logan method) for each brain region (pharmacokinetic analysis population)

| Brain Region          | DVR (2TCM method) | DVR’ (Logan method) |
|-----------------------|-------------------|---------------------|
|                       | HV (N = 16)       | MDD (N = 14)        | HV (N = 22) | MDD (N = 20) |
| Dorsal caudate        |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.64 (0.28)       | 1.68 (0.29)         | 1.65 (0.19)| 1.70 (0.18)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Right                 |                   |                     |            |              |
| Mean (s.d.)           | 1.66 (0.24)       | 1.65 (0.33)         | 1.61 (0.17)| 1.64 (0.20)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Dorsal putamen        |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.71 (0.26)       | 1.77 (0.27)         | 1.73 (0.19)| 1.77 (0.18)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Right                 |                   |                     |            |              |
| Mean (s.d.)           | 1.71 (0.24)       | 1.80 (0.28)         | 1.74 (0.16)| 1.79 (0.18)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Ventral striatum      |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.78 (0.27)       | 2.02 (0.70)         | 1.74 (0.21)| 1.79 (0.20)  |
| P-value*              |                   | < 0.001             | 0.748      |              |
| Right                 |                   |                     |            |              |
| Mean (s.d.)           | 1.71 (0.23)       | 1.81 (0.36)         | 1.70 (0.16)| 1.73 (0.21)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Hippocampus           |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.67 (0.31)       | 1.73 (0.27)         | 1.58 (0.16)| 1.63 (0.19)  |
| P-value*              |                   | 0.020               | < 0.001    |              |
| Right                 |                   |                     |            |              |
| Mean (s.d.)           | 1.62 (0.24)       | 1.67 (0.36)         | 1.56 (0.16)| 1.57 (0.20)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Amygdala              |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.69 (0.22)       | 1.70 (0.34)         | 1.64 (0.13)| 1.65 (0.20)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Right                 |                   |                     |            |              |
| Mean (s.d.)           | 1.71 (0.23)       | 1.73 (0.32)         | 1.65 (0.14)| 1.67 (0.18)  |
| P-value*              |                   | 0.001               | < 0.001    |              |
| Cingulate             |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.62 (0.22)       | 1.74 (0.28)         | 1.62 (0.16)| 1.69 (0.16)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Right                 |                   |                     |            |              |
| Mean (s.d.)           | 1.63 (0.22)       | 1.70 (0.22)         | 1.64 (0.15)| 1.69 (0.12)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Temporal lobe         |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.74 (0.23)       | 1.78 (0.25)         | 1.70 (0.16)| 1.75 (0.14)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Right                 |                   |                     |            |              |
| Mean (s.d.)           | 1.76 (0.23)       | 1.80 (0.23)         | 1.72 (0.16)| 1.76 (0.14)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Parietal lobe         |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.59 (0.17)       | 1.64 (0.23)         | 1.60 (0.11)| 1.63 (0.13)  |
| P-value*              |                   | 0.006               | < 0.001    |              |
| Right                 |                   |                     |            |              |
| Mean (s.d.)           | 1.60 (0.17)       | 1.64 (0.22)         | 1.61 (0.11)| 1.65 (0.12)  |
| P-value*              |                   | 0.007               | < 0.001    |              |
| DLPFC                 |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.60 (0.20)       | 1.66 (0.20)         | 1.60 (0.13)| 1.66 (0.11)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| Right                 |                   |                     |            |              |
| Mean (s.d.)           | 1.62 (0.20)       | 1.66 (0.19)         | 1.62 (0.13)| 1.67 (0.10)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |
| OPFC                  |                   |                     |            |              |
| Left                  |                   |                     |            |              |
| Mean (s.d.)           | 1.67 (0.21)       | 1.69 (0.20)         | 1.65 (0.15)| 1.68 (0.11)  |
| P-value*              |                   | < 0.001             | < 0.001    |              |

DISCUSSION

Metabotropic glutamate receptors, particularly mGluR5, have been implicated in antidepressant action and mood regulation.7
mGluR5 antagonists have been shown to have antidepressant effects,\textsuperscript{6,12,37,38} therefore, an understanding of how mGluR5 availability varies in mood disorders may help devise appropriate treatment strategies. This is particularly important in the elderly, considering the widespread prevalence of MDD in this population, which is an increasing problem as the general population ages. The present study compared regional differences of mGluR5 availability in the brains of elderly patients with MDD and elderly healthy volunteers with comparable demographics, using PET and the radiotracer [\textsuperscript{11}C]ABP688.

Studies have shown that [\textsuperscript{11}C]ABP688 binding is altered following drug-induced perturbations of endogenous glutamate levels in humans,\textsuperscript{39} baboons\textsuperscript{40} and rats\textsuperscript{41} (although findings in rats are not entirely consistent\textsuperscript{42,43}), suggesting that this binding may be sensitive to glutamate variation. As [\textsuperscript{11}C]ABP688 does not bind to the same site as glutamate on mGluR5, we and others have hypothesized that the presence of glutamate may alter [\textsuperscript{11}C]ABP688 affinity for mGluR5.\textsuperscript{39–41} As magnetic resonance spectroscopy studies have reported higher levels of glutamate metabolites in the frontal cortex in depression (including late-life depression),\textsuperscript{44} this variability presents a potential confound for study results. However, metabolite changes were not consistently identified in other brain regions, and as the majority of metabolites measured by magnetic resonance spectroscopy are intracellular, it is difficult to know what, if any, effects on binding this would cause;\textsuperscript{44} especially on global binding as measured in this work. Further, despite potential intersubject variability in glutamate transmission, previous [\textsuperscript{11}C]ABP688 studies in controls have not shown high variance in baseline binding.\textsuperscript{42,43} Moreover, [\textsuperscript{11}C]ABP688 has been successfully used previously to detect mGluR5-binding differences in depression, smoking and obsessive-compulsive disorder, and in response to antidepressant treatment.\textsuperscript{14,15,46,47}

In this study, we observed no statistically significant difference in [\textsuperscript{11}C]ABP688 binding between elderly patients with MDD and elderly healthy volunteers. Moreover, radioligand binding was not found to differ between elderly patients with early-onset and late-onset depression. To our knowledge, this is the first study to evaluate mGluR5 in elderly depression. To improve generalizability, subjects were recruited from two sites. Linear mixed-effects models run using either \(V_T\) or \(DVR\) as the outcome measure indicated that there was a significant effect of center. This could be because of differing characteristics of the subjects recruited at each site or the characteristics of the PET imaging. However, on average (across all regions), the differences in \(DVR\) binding between sites was \(5.5 \pm 2.3\%\) and \(4.6 \pm 3.0\%\) in the controls and depressed subjects, respectively (data not shown). Therefore, although significant, these small differences would not confound a biological signal and are negligible.

The optimal method to quantify [\textsuperscript{11}C]ABP688 binding in the brain is 2TCM.\textsuperscript{14} However, this model requires an arterial input function. As we were unable to obtain an input function for all patients, we also used a reference region-based method to quantify [\textsuperscript{11}C]ABP688 binding. As we have previously shown,\textsuperscript{48} binding estimates based on reference tissue modeling are biased compared with those estimated with an arterial input function. Further, group differences in binding in the reference region can confound depressed/control comparisons, as has been observed in other tracers.\textsuperscript{49} However, in this specific case, use of \(DVR\) likely did not affect the ultimate conclusion as the binding in the reference region (\(V_T\), as assessed with arterial plasma) was not significantly different between groups and a depressed/control comparison (linear mixed effects model) performed only with subjects receiving arterial lines with both radioactivity and metabolite sampling (13 MDD and 11 controls) also yielded insignificant differences.

Deschwanden et al.\textsuperscript{13} found lower levels of mGluR5 binding in patients with MDD compared with healthy controls, and reduced mGluR5 protein expression in the prefrontal cortex of post-mortem brains of depressed subjects. In contrast, in this work, binding in the MDD group was higher than controls on a regional level (although differences did not reach significance), whereas voxel-level analysis yielded no cohort differences. There were several methodological differences between that study and ours, including radioligand administration. In our study, a single bolus, versus bolus plus infusion method, of the tracer was administered. However, these two methods have been shown to yield comparable results.\textsuperscript{33} Although bolus infusion techniques have the advantage of requiring fewer blood samples, potentially less time in the scanner and less computationally expensive modeling, we chose to use a bolus protocol because of the advantages of allowing accurate quantification of whole-brain

---

Figure 1. Comparison of \(DVR\) values from different regions of the brain between elderly patients with major depressive disorder (\(n = 22\)) and elderly healthy volunteers (\(n = 20\)). DLPFC, dorsolateral prefrontal cortex; DVR, distribution volume ratio calculated using Logan; MPRF, medial prefrontal cortex; OPFC, orbital prefrontal cortex.

Figure 2. Comparison of \(DVR\) values from different regions of the brain between elderly patients with major depressive disorder with early (\(n = 16\)) and late (\(n = 4\)) onset depression. DLPFC, dorsolateral prefrontal cortex; DVR, distribution volume ratio calculated using Logan; MPRF, medial prefrontal cortex; OPFC, orbital prefrontal cortex.
binding (including regions with differing kinetics) and reduced dose.10 The SPM analysis used in the present study was also more conservative regarding significance levels and correction for multiple comparisons.13 However, the discrepancies between these two studies are most likely due to differences in patient populations (for example, age, severity of MDD and medication used) and imaging methods. In particular, the age range in that study was 22–59 years. As such, differing results may represent pathological differences between depression in early and late adulthood (for example, mGluR5-mediated versus vascular disease).

Further, there is inconsistency in the literature regarding the role of mGluR5 in depression. A recent post-mortem study showed reduced GRMs (which encodes mGluR5) in depressed subjects (in males only).51 However, in preclinical studies, mGluR5 knockout mice exhibit reduced depression-like behaviors and blockade of mGluR5 produces an antidepressant effect52 (which has also been shown in humans with mGluR5-negative allosteric modulators53). To address these inconsistencies and potential age effects, future studies will need to be performed.

Another potential area for further research is the correlation between MDD symptom severity and mGluR5 availability in different regions of the brain. In the present study, exploratory analyses revealed a positive correlation between GDS score and DVR of \(^{[1]}\)CABP688 in the left hippocampus. In contrast, Deschwanden et al13 reported the opposite tendency and a negative correlation between depressive symptoms, as assessed with the Beck Depression Inventory, and mGluR5 binding in all regions where DVR of \(^{[1]}\)CABP688 was decreased in MDD patients compared with controls (for example, in the parietal, temporal, frontal areas, thalamus and hippocampus). The discrepancy between the two studies may be worthy of further investigation.

No significant relationship was observed between the GADSS and binding in any region, despite the preclinical literature linking anxiety and mGluR5 (refs. 8,54–56) and the use of mGluR5 antagonists as potential anxiolytics.57 However, the present study did demonstrate a significant positive correlation between MMSE score and DVR of \(^{[1]}\)CABP688 in the left ventral striatum and bilateral caudate as well as between MoCA score and DVR in right caudate. This is consistent with previous work showing reduced \(^{[1]}\)CABP688 binding in behavioral variant frontotemporal dementia. However, binding reductions in that work were widespread.58 Caution should be taken in the interpretation of these correlations as these results would not survive correction for multiple comparisons and therefore require further study. However, as this may suggest a link between mGluR5s and neurodegeneration (particularly given the vulnerability of mGluR5s to amyloidosis59,60 and the presence of this and similar pathologies in geriatric populations61,62), future studies designed to investigate the role of mGluR5 in cognitive functioning might be of interest.

In summary, results of the present study found no significant difference in mGluR5 density in the brain of elderly subjects with MDD compared with elderly healthy volunteers. Similarly, no significant difference in binding of \(^{[1]}\)CABP688 between patients with early- or late-onset depression was detected. Further work is required to determine whether this represents differences in the pathophysiology of depression in the elderly, an effect of age on mGluR5 or another mechanism. However, current results provide initial insight into the role of mGluR5 in elderly depression, a growing global problem.

ACKNOWLEDGMENTS
This study was funded by Novartis Pharma AG, Basel, Switzerland. Medical writing and editorial assistance were provided by Fishawack Communications, Oxford, UK; this support was funded by Novartis Pharma AG, Basel, Switzerland. We acknowledge the biostatistical consultation and support from the Biostatistical Consulting Core at the School of Medicine, Stony Brook University. This study was also supported by the National Institute of Mental Health, K01MH091354 (CD).

REFERENCES
1 Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 2006; 113:372–387.
2 Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging 2010; 27:625–640.
3 Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annu Rev Clin Psychol 2009; 5:363–389.
4 Brodaty H, Luscombe G, Parker G, Wilhelm K, Hickie I, Austin MP et al. Early and late onset depression in old age: different aetiologies, same phenomenology. J Affect Disord 2001; 66:225–236.
5 Korten NC, Cornijs HC, Lamers F, Penninx BW. Early and late onset depression in young and middle aged adults: differential symptomatology, characteristics and risk factors? J Affect Disord 2012; 138:259–267.
6 Lebedeva A, Westman E, Lebedev AV, Li X, Winblad B, Simmons A et al. Structural brain changes associated with depressive symptoms in the elderly with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2014; 85:930–935.
7 Spooren W, Lesage A, Lavreyens H, Gasparini F, Steckler T. Metabotropic glutamate receptors: their therapeutic potential in anxiety. Curr Topics Behav Neurosci 2010; 2:391–413.
8 Tatarczyńska E, Kłodzinska A, Chojnacka-Wojcik E, Paluch A, Gasparini F, Kuhn R et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlur receptor antagonist. Br J Pharmacol 2001; 132:1423–1430.
9 Croyan JF, Momberou C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29:571–612.
10 Belozertsyv I, Kost S, Popik P, Danyss W, Bespalov AY. Antidepressant-like effects of mGlur5 and mGlur5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007; 17:172–179.
11 Palucha A, Branski P, Szevczyk B, Wieronska JM, Klak K, Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGlur5 antagonist. Pharmacol Biochem Behav 2005; 81:901–906.
12 Li X, Need AB, Baez M, Wiltin JM. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006; 319:254–259.
13 Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by \(^{[1]}\)CABP688 PET and postmortem study. Am J Psychiatry 2011; 168:727–734.
14 DeLorenzo C, DellaGoia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C et al. In vivo ketamine-induced changes in \(^{[1]}\)CABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry 2014; 77:266–275.
15 Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM et al. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. Biol Psychiatry 2013; 73:161–168.
16 Menard C, Quirion R. Successful cognitive aging in rats: a role for mGluR5 glutamate receptors, homer 1 proteins and downstream signaling pathways. PLoS One 2012; 7:e28666.
17 Domenici MR, Pintor A, Potenza RL, Gaudì S, Gro MC, Passarelli F et al. Metabotropic glutamate receptor 5 (mGlur5)-mediated phosphoinositide hydrolysis and NMDA-potentiating effects are blunted in the striatum of aged rats: a possible additional mechanism in striatal senescence. Eur J Neurosci 2003; 17:2047–2055.
18 Tsamis KI, Mytilinaios DG, Njao SN, Baloyannis SJ. Glutamate receptors in human caudate nucleus in normal aging and Alzheimer’s disease. Curr Alzheimer Res 2013; 10:469–475.
19 DuBois JM, Roussos DG, Rowley L, Porras-Betancourt M, Reader AJ, Labbe A et al. Characterization of age/sex and the regional distribution of mGlur5 availability in the healthy human brain measured by high-resolution \(^{[1]}\)CABP688 PET. J Nucl Med Mol Imaging 2015.
20 Ametamey SM, Kessler LJ, Homer M, Wyss MT, Buck A, Hintermann S et al. Radiosynthesis and preclinical evaluation of \(^{11}C\)-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 2006; 47:698–705.
Population-based input function and image-derived input function for [(11)C](R)-fi

2018; 157: – 157.

2014; 11: 125–136.

2015; 116: – 116.

2013; 109: 1954 – 1954.

2012; 116: 1169 – 1174.

2013; 117: 1184 – 1184.

2012; 11: 1130 – 1130.

2011; 110: 1110 – 1110.

2010; 163: 163 – 163.

2009; 139: 139 – 139.

2008; 147: 147 – 147.

2007; 146: 146 – 146.

2006; 145: 145 – 145.

2005; 144: 144 – 144.

2004; 143: 143 – 143.

2003; 142: 142 – 142.

2002; 141: 141 – 141.

2001; 140: 140 – 140.

2000; 139: 139 – 139.

1999; 138: 138 – 138.

1998; 137: 137 – 137.

1997; 136: 136 – 136.

1996; 135: 135 – 135.

1995; 134: 134 – 134.

1994; 133: 133 – 133.

1993; 132: 132 – 132.

1992; 131: 131 – 131.

1991; 130: 130 – 130.

1990; 129: 129 – 129.

1989; 128: 128 – 128.

1988; 127: 127 – 127.

1987; 126: 126 – 126.

1986; 125: 125 – 125.

1985; 124: 124 – 124.

1984; 123: 123 – 123.

1983; 122: 122 – 122.

1982; 121: 121 – 121.

1981; 120: 120 – 120.

1980; 119: 119 – 119.

1979; 118: 118 – 118.

1978; 117: 117 – 117.

1977; 116: 116 – 116.

1976; 115: 115 – 115.

1975; 114: 114 – 114.

1974; 113: 113 – 113.

1973; 112: 112 – 112.

1972; 111: 111 – 111.

1971; 110: 110 – 110.

1970; 109: 109 – 109.

1969; 108: 108 – 108.

1968; 107: 107 – 107.

1967; 106: 106 – 106.

1966; 105: 105 – 105.

1965; 104: 104 – 104.

1964; 103: 103 – 103.

1963; 102: 102 – 102.

1962; 101: 101 – 101.

1961; 100: 100 – 100.

1960; 99: 99 – 99.